Symbols

CDNA

CareDx·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CDNA

Caredx, Inc.

A leading precision medicine solutions company that focused on developing healthcare solutions for transplant patients and caregivers

Industry

Healthcare Equipment and Supplies

Established Date

12/21/1998

Listing Date

07/17/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

761

Fiscal Year Ends

12-31

Website

www.caredx.com

Security Type

Common stock

Office address

8000 Marina Boulevard, Brisbane, California 94005

Business

Introduction

CareDx, Inc., was incorporated in Delaware on December 21, 1998 as Hippocratic Engineering, Inc. In April 1999, they changed their name to BioCardia, Inc., and in June 2002, they changed their name to Expression Diagnostics, Inc. In July 2007, they changed their name to XDX, Inc., and in March 2014, they changed their name to CareDx, Inc. CareDx is a precision medicine company dedicated to improving the prognosis of transplant patients and promoting organ health. Their headquarters are in Brisbane, California. The solutions they offer are designed to empower clinicians and improve patient outcomes. The company's all-in-one solutions include non-invasive molecular testing for heart, kidney and lung transplants; laboratory products; digital health technology; and patient solutions that support pre- and post-transplant care.

Company Financials

EPS

CDNA has released its 2025 Q4 earnings. EPS was reported at 0.12, versus the expected 0.01, beating expectations. The chart below visualizes how CDNA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CDNA has released its 2025 Q4 earnings report, with revenue of 108.39M, reflecting a YoY change of 25.19%, and net profit of -4.11M, showing a YoY change of -104.68%. The Sankey diagram below clearly presents CDNA's revenue sources and cost distribution.